Abstract | PURPOSE:
Dry eye syndrome is commonly thought of as an inflammatory disease, and we have previously presented data showing the effectiveness of topical TNF-α blocker agents for the treatment of this condition. The purpose of this study was to investigate the effectiveness of the TNF-α blocking agent HL036337 compared to cyclosporine A for the treatment of dry eye induced inflammation in order to establish whether HL036337 represents a more effective method for suppressing inflammation. The efficacy of HL036337 and cyclosporine A was determined using an experimental murine dry eye model. METHODS: The TNF-α blocker HL036337 is a modified form of TNF receptor I. Using dry eye induced C57BL/6 mice (n = 45), corneal erosion was measured at day 4 and 7 after topical treatment with cyclosporine A or HL036337. To determine the effective treatment dose, 0.25, 0.5, 1, 2.5, and 5 mg/mL of HL036337 were topically administered twice per day to dry eye induced murine corneas for 1 week. RESULTS: The optimal concentration of the TNF-α blocker HL036337 for treatment of dry eye induced corneal erosion was determined to be 1 mg/mL. Dry eye induced corneal erosion was improved after 1 week with topically applied cyclosporine A and HL036337 at 1 mg/mL. CONCLUSIONS: HL036337 administered topically at 1 mg/mL effectively improved corneal erosion induced by dry eye. This finding may also suggest that inhibition of TNF-α can improve dry eye syndrome.
|
Authors | Wungrak Choi, Hyemi Noh, Areum Yeo, Hanmil Jang, Hyea Kyung Ahn, Yeon Jung Song, Hyung Keun Lee |
Journal | Korean journal of ophthalmology : KJO
(Korean J Ophthalmol)
Vol. 30
Issue 4
Pg. 302-8
(Aug 2016)
ISSN: 2092-9382 [Electronic] Korea (South) |
PMID | 27478358
(Publication Type: Journal Article)
|
Chemical References |
- Ophthalmic Solutions
- Tumor Necrosis Factor-alpha
|
Topics |
- Animals
- Cornea
(diagnostic imaging)
- Disease Models, Animal
- Dose-Response Relationship, Drug
- Dry Eye Syndromes
(diagnosis, drug therapy)
- Female
- Mice
- Mice, Inbred C57BL
- Microscopy, Acoustic
- Ophthalmic Solutions
(administration & dosage)
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors)
|